跳至主要内容
临床试验/JPRN-jRCT1040220052
JPRN-jRCT1040220052招募中未知

Observational study to establish evaluation method for vascular abnormalities using deep learning

Michio Ozeki0 个研究点目标入组 20 人开始时间: 2022年8月11日最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 1, A multicenter phase III investigator-initiated clinical trial (NPC-12T-LM study) conducted from 2017 to 2019 to investigate the efficacy and safety of NPC-12T (sirolimus) for intractable lymphatic disease, Multi-center, open-label, uncontrolled study to investigate the safety and efficacy of sirolimus for refractory vascular and lymphatic diseases (SRL-CVA-01 study, jRCTs031180290) started in 2017, and Conducted from 2020 to 2022, a multicenter phase III investigator-initiated clinical trial (NPC -12T-CVA)
  • 2) Patients with evaluable MRI images
  • 3) Patients who agreed to participate in this study

排除标准

  • 1) Patients with other than obvious vascular abnormalities
  • 2) Patients with clearly different lesions and image artifacts such as bleeding and inflammation that are difficult to evaluate
  • 3) Other patients who are judged to be inappropriate by the principal investigator or co-investigator

研究者

发起方
Michio Ozeki

相似试验